We are initiating coverage of Mateon Therapeutics, Inc. (OTC:MATN) with a valuation of $0.40. Mateon is a biopharmaceutical company developing drug candidates for difficult to treat cancers and viral ...
On February 2, 2021, Mateon Therapeutics, Inc. (OTC:MATN) announced that the ARTI-19 trial of ARTIVedaâ„¢/PulmoHealâ„¢ against COVID-19 in India has completed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback